Hematopoietic stem cell transplantation after posttransplant lymphoproliferative disorder / Min Joo Kim ; Inho Kim ; Hyun-Mi Bae ; Kyungsuk Seo ; Namjun Park ; Sung-Soo Yoon ; Seonyang Park ; Byoung Kook Kim 1
[요약] 1
Introduction 1
Case report 1
Discussion 3
References 4
초록보기
A 16-yr-old girl received liver transplantation for fulminant hepatitis. Aplastic anemia
developed, and she received hematopoietic stem cell transplantation (HSCT).
Eleven months after liver transplantation, abdominal lymph node enlargement and
colon ulcers were observed, and colon biopsy showed posttransplant lymphoproliferative
disorder (PTLD). Immunosuppression reduction was attempted, but it produced
no therapeutic effect. Fourteen months after liver transplantation, she received
a second HSCT due to engraftment failure, and PTLD resolved completely. The
second HSCT can serve as cellular therapy for PTLD.
Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-7.
미소장
2
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
미소장
3
Pretransplantation Assessment of the Risk of Lymphoproliferative Disorder
미소장
4
An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation.
미소장
5
LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN THERAPY
미소장
6
Posttransplant malignancy
미소장
7
Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies.
미소장
8
The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
미소장
9
Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.
미소장
10
Epstein-Barr virus infection.
미소장
11
Epstein–Barr virus and lymphoproliferative disorders after transplantation
미소장
12
The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
미소장
13
Rituximab (Chimeric Anti-CD20 Antibody) for Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation in Adults: Long-Term Experience from a Single Center
미소장
14
Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
미소장
15
Rituximab in association with rapamycin for post‐transplant lymphoproliferative disease treatment
미소장
16
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
미소장
17
Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts
미소장
18
COMPLETE REGRESSION OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE USING PARTIALLY HLA-MATCHED EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T CELLS1
미소장
19
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
미소장
20
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells